CN103330932B - The pharmaceutical composition of a kind of MFG or its salt - Google Patents
The pharmaceutical composition of a kind of MFG or its salt Download PDFInfo
- Publication number
- CN103330932B CN103330932B CN201310150069.8A CN201310150069A CN103330932B CN 103330932 B CN103330932 B CN 103330932B CN 201310150069 A CN201310150069 A CN 201310150069A CN 103330932 B CN103330932 B CN 103330932B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- mfg
- antifungal pharmaceutical
- glucosan
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses the pharmaceutical composition of a kind of MFG or its salt, said composition for excipient, and can contain qs pH adjuster with polysaccharide or monosaccharide or its mixture.Pharmaceutical composition stability provided by the invention and potential safety are better than existing preparation.
Description
Technical field
The present invention relates to the stabilizing pharmaceutical composition of ring type polypeptide compound MFG.Specifically, the present invention relates to MFG and pharmaceutically acceptable salt thereof for active component, the stable pharmaceutical composition being excipient with polysaccharide or monosaccharide or its mixture.
Background technology
MFG is after Caspofungin, the second echinocandin antifungal agent thing of FDA approval.Injection FK463, commodity are called meter Kai Min, are to be developed by Japanese Astellas Pharma Inc, within 2002, first in Japan's listing, within 2005, are ratified by FDA, and enter China in 2006.Its clinical trial shows, compared with Caspofungin, the bacteriostatic activity of MFG is stronger, and minimal effective concentration is lower, and adverse reaction rate is lower.
Patent CN1179748C is FK463 formulation patent, take wherein lactose as excipient, prepares the pharmaceutical composition of FK463 lyophilized form.Commercially available lactose extracts the residual liquid after cheese and casein by milk to produce.Most Chinese people, to lactose intolerance, there will be the symptoms such as abdominal cavity spasm, diarrhoea, flatulence.And the foreign protein in lactose may cause serious anaphylaxis and cause life danger.Therefore in lyophilized injectable powder, use lactose as excipient, particularly use in non-antitumor drug, relative risk is higher.
Patent CN100352495C is similarly FK463 formulation patent, is take maltose as excipient, prepares the pharmaceutical composition of FK463 lyophilized form.Maltose is applied to solid preparation usually, can be used as sweeting agent and tablet filler.Once reported, the patient of renal failure, after the maltose venous transfusion of application immunoglobulin 10%, causes hyponatremia.Think at present, caused by maltose and the accumulation of other Thief zone active metabolites, to show that maltose is not suitable for intravenous infusion administration, namely using maltose as the excipient of freeze-dried powder, there is certain risk.
Patent CN102614491A is similarly FK463 formulation patent, take wherein trehalose as excipient, prepares the pharmaceutical composition of FK463 lyophilized form.Trehalose is usually used in cosmetics and food, is not included by the pharmacopeia of any country or adjuvant data base at present.It can thus be appreciated that it not can be used in medicine trehalose by any authorized by state, and it should not be used for medicine adjuvant, the excipient of venoclysis freeze-dried powder more can not be used as.In addition, the Thief zone of trehalose in internal organs organ is active, can cause the untoward reaction such as the gastrointestinal upset of patient.Therefore, there is larger potential safety hazard in the excipient using trehalose as MFG sodium freeze-drying powder.
Evident in efficacy due to FK463 is the first-line drug for the treatment of candidiasis and aspergillin infection at present.Therefore in the urgent need to developing effectively and the MFG composition of sodium of safety.
Summary of the invention
The invention provides a kind of safe, effective and stable for antifungal pharmaceutical composition, described compositions comprises:
1) formula (I) MFG or its pharmaceutically-acceptable salts; With
2) pharmaceutically acceptable polysaccharide or monosaccharide or its mixture are as excipient,
Optionally, said composition also comprises pH adjusting agent; Wherein,
Preferably, described polysaccharide is glucosan, starch, cellulose or high fructose, preferred dextran;
Preferably, described monosaccharide is glucose, fructose or rhamnose, preferred glucose;
Preferably, described pharmaceutically-acceptable salts is FK463;
Preferably, the weight ratio of described MFG and excipient is 1:2 ~ 1:15;
Preferably, this pharmaceutical composition is lyophilized injectable powder, and preferably, wherein moisture is not more than 3.6%.
Further, following preferred version is comprised in such scheme:
Wherein said excipient is the mixture of glucosan and glucose, and more preferably, the weight ratio of described glucosan and glucose is 1:0.5 ~ 1:5, and more preferably the weight ratio of glucosan and glucose is 1:1;
Wherein said pH adjusting agent is citric acid, hydrochloric acid, acetic acid, sodium dihydrogen phosphate or sodium hydroxide, preferably citric acid and/or sodium hydroxide.
Another object of the present invention is to provide a kind of for the purposes of antifungal pharmaceutical composition in the medicine preparing prevention or treatment infectious disease, preferably, described infectious disease is selected from by aspergillosis and the microbial infectious disease of beads.
In addition, MFG pharmaceutical composition provided by the invention, by redissolving, after dilution, by the mode administration of venoclysis with pharmaceutically acceptable sodium chloride or glucose injection.
Present invention also offers the preparation method of MFG pharmaceutical composition, the method comprises the following steps:
(1) excipient or vehicle composition are dissolved in appropriate pure water;
(2) MFG is dissolved in excipient aqueous solution prepared by step (1);
(3) adopt 0.1mol/L aqueous solution of citric acid and/or 0.1mol/L sodium hydrate aqueous solution, solution ph prepared by step (2) is adjusted to 5.5;
(4) add pure water, solution prepared by step (3) is settled to volume, after filtration, fill, adopt conventional method lyophilizing.
The pharmaceutical composition of MFG provided by the present invention or its pharmaceutically-acceptable salts, stability is better than existing preparation.Under 40 DEG C of conditions 30 days, under 60 DEG C of conditions 10 days, lyophilizing finished product appearance stablity prepared by the embodiment of the present invention, active component without obvious degradation, show MFG pharmaceutical composition prepared by the present invention can Long-term Storage under room temperature condition.In addition, under equal freeze-dry process condition, MFG pharmaceutical composition prepared by the embodiment of the present invention, moisture is far below existing preparation, and show to require low to dry run in freeze-dry process of the present invention, energy efficient more, significantly can reduce production cost.
In MFG sodium freeze-drying powder compositions provided by the invention, with the higher glucosan, glucose, fructose etc. of safety for excipient.These three kinds of adjuvants are usually used in the injection of intravenously administrable, and glucosan belongs to blood plasma substitute, is mainly used in treating various shock; Glucose and fructose are also commonly used in injection, for supplementary health nutrition.And the research on maximum utilized quantity that specifies much smaller than FDA non-active ingredient data base of the consumption of three in the present invention.Wherein glucose is 45.5%(at the research on maximum utilized quantity that FDA non-active ingredient data base specifies
http:// www.accessdata.fda.gov/scripts/cder/iig/getiigWEB.cfm); Glucosan is 30%(at the research on maximum utilized quantity that FDA non-active ingredient data base specifies
http:// www.accessdata.fda.gov/scripts/cder/iig/getiigWEB.cfm); Fructose is 5%(at the research on maximum utilized quantity that FDA non-active ingredient data base specifies
http:// www.accessdata.fda.gov/scripts/cder/iig/getiigWEB.cfm).It can thus be appreciated that the excipient that the present invention adopts is safer, and untoward reaction is few, is more suitable for the body constitution of our people.And the effectiveness of MFG sodium pharmaceutical composition prepared by the present invention is equal to existing preparation, and stability and safety are better than existing preparation.
Detailed description of the invention
Below in conjunction with specific embodiment, embodiment of the present invention are described in detail.Embodiment is only for illustration of the present invention below, and should not be considered as limiting scope of the present invention.
Embodiment 1
Be dissolved at ambient temperature in 750ml pure water by macrodex, then add FK463, standing or gentle agitation is dissolved complete to crude drug.In solution, add 0.1mol/L aqueous solution of citric acid and/or 0.1mol/L sodium hydrate aqueous solution appropriate, solution ph is adjusted to 5.5.Then 1250ml is diluted to pure water.Gained solution is divided and is filled in 500 10ml control antibiotic bottles, every bottle of 2.5ml.Use conventional freeze dryer, adopt conventional method lyophilizing, to obtain respectively containing the freeze-dried composition of 50mg MFG.
Embodiment 2
Dextran-20 and glucose are dissolved at ambient temperature in 750ml pure water, then add FK463, standing or gentle agitation is dissolved complete to crude drug.In solution, add 0.1mol/L hydrochloric acid solution and/or 0.1mol/L sodium hydrate aqueous solution appropriate, solution ph is adjusted to 5.5.Then 1250ml is diluted to pure water.Gained solution is divided and is filled in 500 10ml control antibiotic bottles, every bottle of 2.5ml.Use conventional freeze dryer, adopt conventional method lyophilizing, to obtain respectively containing the freeze-dried composition of 50mg MFG.
Embodiment 3
Dextran 40 and glucose are dissolved at ambient temperature in 750ml pure water, then add FK463, standing or gentle agitation is dissolved complete to crude drug.In solution, add 0.1mol/L aqueous solution of citric acid and/or 0.1mol/L sodium hydrate aqueous solution appropriate, solution ph is adjusted to 5.5.Then 1250ml is diluted to pure water.Gained solution is divided and is filled in 500 10ml control antibiotic bottles, every bottle of 2.5ml.Adopt conventional method lyophilizing, to obtain respectively containing the freeze-dried composition of 50mg MFG.
Embodiment 4
Dextran 40 and fructose are dissolved at ambient temperature in 750ml pure water, then add FK463, standing or gentle agitation is dissolved complete to crude drug.In solution, add 0.1mol/L acetum and/or 0.1mol/L sodium hydrate aqueous solution appropriate, solution ph is adjusted to 5.5.Then 1250ml is diluted to pure water.Gained solution is divided and is filled in 500 10ml control antibiotic bottles, every bottle of 2.5ml.Adopt conventional method lyophilizing, to obtain respectively containing the freeze-dried composition of 50mg MFG.
Embodiment 5
Macrodex and glucose are dissolved in (750ml) in 750ml pure water at ambient temperature, then add FK463, standing or gentle agitation is dissolved complete to crude drug.In solution, add 0.1mol/L sodium dihydrogen phosphate and/or 0.1mol/L sodium hydrate aqueous solution appropriate, solution ph is adjusted to 5.5.Then 1250ml is diluted to pure water.Gained solution is divided and is filled in 500 10ml control antibiotic bottles, every bottle of 2.5ml.Adopt conventional method lyophilizing, to obtain respectively containing the freeze-dried composition of 50mg MFG.
Embodiment 6
Dextran-20 and glucose are dissolved at ambient temperature in 750ml pure water, then add FK463, standing or gentle agitation is dissolved complete to crude drug.In solution, add 0.1mol/L aqueous solution of citric acid and/or 0.1mol/L sodium hydrate aqueous solution appropriate, solution ph is adjusted to 5.5.Then 1250ml is diluted to pure water.Gained solution is divided and is filled in 500 10ml control antibiotic bottles, every bottle of 2.5ml.Adopt conventional method lyophilizing, to obtain respectively containing the freeze-dried composition of 50mg MFG.
Comparative example 1:
Be dissolved in by lactose (less than 50 DEG C water-baths) in 2000ml pure water, be cooled to less than 20 DEG C, in lactose solution, add FK463, gentle agitation makes it dissolve, and avoids producing bubble in process.After adding 2% aqueous solution of citric acid (9.5ml) again, in solution, add 0.4% sodium hydrate aqueous solution (about 24ml), regulate the pH to 5.5 of medicinal liquid, then with pure water dilution, be settled to 2500ml.Gained solution is dispensed in 1000 10ml control antibiotic bottles, each bottle of 2.5ml.Use conventional method lyophilizing, to obtain respectively containing the freeze-dried composition of 50mg MFG.
Comparative example 2:
Be dissolved in by glucosan (less than 50 DEG C water-baths) in 2000ml pure water, be cooled to less than 20 DEG C, in dextran solution, add FK463, gentle agitation makes it dissolve, and avoids producing bubble in process.After adding 2% aqueous solution of citric acid (9.5ml) again, in solution, add 0.4% sodium hydrate aqueous solution (about 24ml), to regulate pH5.5, then with pure water dilution, be settled to volume 2500ml.Gained solution is dispensed in 1000 10ml control antibiotic bottles, every bottle of 2.5ml.Use conventional method lyophilizing, to obtain respectively containing the freeze-dried composition of 50mg MFG.
Comparative example 3:
Be dissolved in by trehalose (less than 50 DEG C water-baths) in 2000ml pure water, be cooled to less than 20 DEG C, in aqueous trehalose, add FK463, gentle agitation makes it dissolve, and avoids producing bubble in process.Adopt 2% aqueous solution of citric acid or 0.4% sodium hydrate aqueous solution, regulate pH to 5.5, then with pure water dilution, be settled to volume 2500ml.Gained solution is dispensed in 1000 10ml control antibiotic bottles, every bottle of 2.5ml.Use conventional method lyophilizing, to obtain respectively containing the freeze-dried composition of 50mg MFG.
MFG preparation stability compares
Investigate the sample of above-mentioned 6 embodiments and 3 comparative examples, carry out 40 DEG C and 60 DEG C of study on the stability respectively.Analyze active substance with HPLC, analytical column ODSC18 post used, specification: 250C18 analyzes, S-5 μm.Column temperature: 25 DEG C, 210nm detects, mobile phase: A:0.5% sodium dihydrogen phosphate; B: acetonitrile.Gradient: B0 ' (3%) ~ 5 ' (8%) ~ 15 ' (40%) ~ 25 ' (50%) ~ 35 ' (50%) ~ 36 ' (3%) ~ 43 ' (3%).The content of MFG is calculated by external standard method.Investigation the results are shown in Table 1 ~ 2.
The table 140 DEG C study on the stability result of month
The table 260 DEG C study on the stability result of 10 days
Can be found out by the data of table 1 and table 2:
(1) under the high temperature conditions, MFG pharmaceutical composition prepared by the embodiment of the present invention, stability is significantly better than three comparative examples.MFG pharmaceutical composition prepared by three comparative examples, under 40 DEG C and 60 DEG C of conditions, total impurities significantly increases, less stable, is not suitable for medicinal exploitation.Pharmaceutical composition prepared by the embodiment of the present invention, finished appearance is stablized under the high temperature conditions, and active component is without obvious degradation.Show MFG pharmaceutical composition prepared by the present invention can Long-term Storage under room temperature condition, the cost of storage is low.
(2) in the embodiment of the present invention, embodiment 3 with the mixture of Dextran 40 and glucose 1:1 for excipient, the MFG pharmaceutical composition of preparation, optimal stability.
(3) from the moisture data in two tables, under equal freeze-dry process condition, MFG pharmaceutical composition prepared by the embodiment of the present invention, moisture is far below comparative example.Show to require low to dry run in freeze-dry process of the present invention, energy efficient more, significantly can reduce production cost.
Claims (13)
1. for an antifungal pharmaceutical composition, it is characterized in that, described compositions comprises:
1) MFG shown in formula (I) or its pharmaceutically-acceptable salts; With
2) pharmaceutically acceptable polysaccharide and mixture of monosaccharides are as excipient,
Optionally, said composition also comprises pH adjusting agent,
Wherein said polysaccharide is glucosan, and described monosaccharide is glucose, and described pharmaceutical composition is lyophilized injectable powder, and the weight ratio of described glucosan and glucose is 1:0.5 ~ 1:5.
2. according to claim 1 for antifungal pharmaceutical composition, wherein said glucosan is selected from dextran.
3. according to claim 1 for antifungal pharmaceutical composition, wherein said glucosan is selected from Dextran-20, Dextran 40 or macrodex.
4. according to claim 1 for antifungal pharmaceutical composition, wherein said pharmaceutically-acceptable salts is FK463.
5. according to claim 1 for antifungal pharmaceutical composition, the weight ratio of wherein said MFG and excipient is 1:2 ~ 1:15.
6. according to claim 1 for antifungal pharmaceutical composition, wherein moisture is not more than 3.6%.
7. according to claim 1 for antifungal pharmaceutical composition, wherein moisture is not more than 2%.
8. according to claim 1 for antifungal pharmaceutical composition, wherein the weight ratio of glucosan and glucose is 1:1.
9. according to claim 1 ~ 8 any one for antifungal pharmaceutical composition, wherein said pH adjusting agent is selected from citric acid, hydrochloric acid, acetic acid, sodium dihydrogen phosphate and/or sodium hydroxide.
10. according to claim 1 ~ 8 any one for antifungal pharmaceutical composition, wherein said pH adjusting agent is selected from citric acid and/or sodium hydroxide.
11. according to claim 1 ~ 8 any one for antifungal pharmaceutical composition in preparation prevention or treatment by the purposes in the medicine of aspergillosis and the microbial infectious disease of beads.
12. according to claim 9 for antifungal pharmaceutical composition in preparation prevention or treatment by the purposes in the medicine of aspergillosis and the microbial infectious disease of beads.
13. according to claim 10 for antifungal pharmaceutical composition in preparation prevention or treatment by the purposes in the medicine of aspergillosis and the microbial infectious disease of beads.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310150069.8A CN103330932B (en) | 2013-04-26 | 2013-04-26 | The pharmaceutical composition of a kind of MFG or its salt |
| PCT/CN2014/072683 WO2014173204A1 (en) | 2013-04-26 | 2014-02-28 | Pharmaceutical composition of micafungin or salt thereof |
| TW103113514A TWI634897B (en) | 2013-04-26 | 2014-04-14 | Pharmaceutical composition of micafungin or the salts thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310150069.8A CN103330932B (en) | 2013-04-26 | 2013-04-26 | The pharmaceutical composition of a kind of MFG or its salt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103330932A CN103330932A (en) | 2013-10-02 |
| CN103330932B true CN103330932B (en) | 2015-12-23 |
Family
ID=49239182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310150069.8A Active CN103330932B (en) | 2013-04-26 | 2013-04-26 | The pharmaceutical composition of a kind of MFG or its salt |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN103330932B (en) |
| TW (1) | TWI634897B (en) |
| WO (1) | WO2014173204A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103330932B (en) * | 2013-04-26 | 2015-12-23 | 江苏豪森药业股份有限公司 | The pharmaceutical composition of a kind of MFG or its salt |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100352495C (en) * | 1999-07-01 | 2007-12-05 | 安斯泰来制药有限公司 | Stabilized pharmaceutical composition in lyophilized form |
| CN102512659A (en) * | 2011-01-31 | 2012-06-27 | 上海天伟生物制药有限公司 | Medicinal composition containing echinocandin antifungal agent and its preparing method and its use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1156784A1 (en) * | 1999-03-03 | 2001-11-28 | Eli Lilly And Company | Processes for making pharmaceutical oral ecb formulations and compositions |
| CN102614491B (en) * | 2011-01-31 | 2014-04-16 | 上海天伟生物制药有限公司 | Pharmaceutical composition containing echinocandin antifungal agent micafungin, its preparation method and application |
| CN103330932B (en) * | 2013-04-26 | 2015-12-23 | 江苏豪森药业股份有限公司 | The pharmaceutical composition of a kind of MFG or its salt |
-
2013
- 2013-04-26 CN CN201310150069.8A patent/CN103330932B/en active Active
-
2014
- 2014-02-28 WO PCT/CN2014/072683 patent/WO2014173204A1/en active Application Filing
- 2014-04-14 TW TW103113514A patent/TWI634897B/en active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100352495C (en) * | 1999-07-01 | 2007-12-05 | 安斯泰来制药有限公司 | Stabilized pharmaceutical composition in lyophilized form |
| CN102512659A (en) * | 2011-01-31 | 2012-06-27 | 上海天伟生物制药有限公司 | Medicinal composition containing echinocandin antifungal agent and its preparing method and its use |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI634897B (en) | 2018-09-11 |
| TW201440782A (en) | 2014-11-01 |
| CN103330932A (en) | 2013-10-02 |
| WO2014173204A1 (en) | 2014-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102614491B (en) | Pharmaceutical composition containing echinocandin antifungal agent micafungin, its preparation method and application | |
| CN102670497A (en) | Stable S-oxiracetam preparation for injection and preparation method of same | |
| CN102068453B (en) | Stable complex vitamin composition and preparation method thereof | |
| CN103315969B (en) | Caspofungin formulations of a kind of low impurity content and its production and use | |
| CA2488872A1 (en) | Antifungal parenteral products | |
| CN101062044B (en) | Medicine combination including high-concentration polydatin | |
| CN102614492B (en) | Liquid pharmaceutical composition containing echinocandin antifungal agent micafungin | |
| CN103330933B (en) | Pharmaceutical composition containing MFG or its salt | |
| WO2008086698A1 (en) | A forsythoside injection and preparation thereof | |
| CN103330932B (en) | The pharmaceutical composition of a kind of MFG or its salt | |
| EP2887953A2 (en) | Improved daptomycin injectable formulation | |
| CN102512379B (en) | A kind of novel Echinocandin antifungal pharmaceutical composition and preparation method thereof | |
| CN102688183B (en) | A kind of stable moxifloxacin hydrochloride injection | |
| CN102335118B (en) | Freeze-dried voriconazole micelle preparation and preparation method thereof | |
| CN100396289C (en) | Scutellarin injection preparation and its preparing method | |
| CN105769756B (en) | A kind of fumaric acid Sitafloxacin hydrate injection and preparation method thereof | |
| CN102614493B (en) | Liquid pharmaceutical composition containing echinocandin antifungal agent caspofungin | |
| CN109078001A (en) | A kind of novel vancomycin nano liposomes composition and preparation method thereof | |
| WO2019047812A1 (en) | Pharmaceutical composition of docetaxel conjugate and preparation method | |
| CN103585119A (en) | Stabilization preparation containing epoprostenol and medical salt of epoprostenol and preparation method of stabilization preparation | |
| CN1287776C (en) | Process for preparing houttuyninum sodium injection | |
| CN108159005A (en) | Injection composition | |
| JP2023553106A (en) | Improved lyophilized formulation | |
| CN103230372B (en) | Lomefloxacin hydrochloride for injection powder pin and preparation method thereof | |
| CN1562007A (en) | Pyrithioxine hydrochloride freeze-dried composition and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant before: JIANGSU HANSOH PHARMACEUTICAL GROUP LIANYUNGANG HONGCHUANG PHARMACEUTICAL Co.,Ltd. |
|
| COR | Change of bibliographic data | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Patentee after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Patentee before: Jiangsu best Pharmaceutical Co.,Ltd. Patentee before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Patentee after: Jiangsu best Pharmaceutical Co.,Ltd. Patentee after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Patentee before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Patentee before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20160323 Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Patentee after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Patentee before: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. |